K
Kazuhiro Asami
Researcher at Nagoya University
Publications - 34
Citations - 4764
Kazuhiro Asami is an academic researcher from Nagoya University. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 14, co-authored 33 publications receiving 4394 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
Tomoya Kawaguchi,Masahiko Ando,Kazuhiro Asami,Yoshio Okano,Masaaki Fukuda,Hideyuki Nakagawa,Hidenori Ibata,Toshiyuki Kozuki,Takeo Endo,Atsuhisa Tamura,Mitsuhiro Kamimura,Kazuhiro Sakamoto,Michihiro Yoshimi,Yoshifumi Soejima,Yoshio Tomizawa,Shun-ichi Isa,Minoru Takada,Hideo Saka,Akihito Kubo +18 more
TL;DR: Erlotinib failed to show an improvement in PFS or OS compared with docetaxel in an EGFR-unselected patient population of patients with advanced non-small-cell lung cancer in an epidermal growth factor receptor (EGFR) -un selected patient population.
Journal ArticleDOI
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +19 more
TL;DR: Overall survival was re-evaluated using updated data and multivariate analysis using Cox proportional hazards model revealed that none of covariates (treatment arm, smoking status, sex, age, postoperative recurrence or IIIB/IV, and mutation type) significantly affected OS.
Journal ArticleDOI
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study
Isamu Okamoto,Hiroshige Yoshioka,Satoshi Morita,Masahiko Ando,Koji Takeda,Takashi Seto,Nobuyuki Yamamoto,Hideo Saka,Kazuhiro Asami,Tomonori Hirashima,Shinzoh Kudoh,Miyako Satouchi,Norihiko Ikeda,Yasuo Iwamoto,Toshiyuki Sawa,Masaki Miyazaki,Kenji Tamura,Takayasu Kurata,Masahiro Fukuoka,Kazuhiko Nakagawa +19 more
TL;DR: Oral S-1 with carboplatin was noninferior in terms of OS compared withcarboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.
Journal ArticleDOI
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations
Kenichi Nishie,Tomoya Kawaguchi,Akihiro Tamiya,Tomoyasu Mimori,Naoko Takeuchi,Yoshinobu Matsuda,Naoki Omachi,Kazuhiro Asami,Kyoichi Okishio,Shinji Atagi,Tomohisa Okuma,Akihito Kubo,Yoshihito Maruyama,Shinzoh Kudoh,Minoru Takada +14 more
TL;DR: Continuous use of EGFR-TKI beyond progressive disease (PD) may prolong overall survival compared with switching to cytotoxic chemotherapy in patients with activating EGFR mutations.